$2.76 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | Buy | VIATRIS INC | $250,240,000 | +15.6% | 23,000,000 | +43.8% | 9.05% | +21.7% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $231,920,000 | +8.4% | 1,600,000 | -3.0% | 8.39% | +14.1% |
| SNY | Buy | SANOFIsponsored adr | $205,360,000 | +7.9% | 4,000,000 | +5.3% | 7.43% | +13.5% |
| ZBH | Buy | ZIMMER BIOMET HOLDINGS INC | $172,665,000 | +35.9% | 1,350,000 | +35.0% | 6.25% | +43.1% |
| GILD | Buy | GILEAD SCIENCES INC | $148,625,000 | -9.0% | 2,500,000 | +11.1% | 5.38% | -4.3% |
| CHNG | Buy | CHANGE HEALTHCARE INC | $130,800,000 | +52.9% | 6,000,000 | +50.0% | 4.73% | +61.0% |
| MRK | Sell | MERCK & CO INC | $123,075,000 | -35.8% | 1,500,000 | -40.0% | 4.45% | -32.4% |
| BKD | BROOKDALE SR LIVING INC | $112,800,000 | +36.6% | 16,000,000 | 0.0% | 4.08% | +43.8% | |
| IONS | Buy | IONIS PHARMACEUTICALS INC | $111,120,000 | +162.7% | 3,000,000 | +115.8% | 4.02% | +176.5% |
| WBA | Sell | WALGREENS BOOTS ALLIANCE INC | $107,448,000 | -41.1% | 2,400,000 | -31.4% | 3.89% | -38.0% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $107,415,000 | +44.6% | 1,375,000 | +66.7% | 3.88% | +52.2% |
| INCY | Buy | INCYTE CORP | $107,217,000 | +62.3% | 1,350,000 | +50.0% | 3.88% | +70.8% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $100,230,000 | +11.8% | 1,300,000 | +28.1% | 3.63% | +17.7% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $98,664,000 | +17.0% | 1,200,000 | +108.7% | 3.57% | +23.1% |
| PRGO | Buy | PERRIGO CO PLC | $96,075,000 | +43.2% | 2,500,000 | +44.9% | 3.48% | +50.7% |
| MYGN | Buy | MYRIAD GENETICS INC | $88,200,000 | +16.2% | 3,500,000 | +27.3% | 3.19% | +22.3% |
| PTCT | Buy | PTC THERAPEUTICS INC | $65,293,000 | +118.6% | 1,750,000 | +133.3% | 2.36% | +130.0% |
| THC | Sell | TENET HEALTHCARE CORP | $58,023,000 | -40.8% | 675,000 | -43.8% | 2.10% | -37.7% |
| MDT | New | MEDTRONIC PLC | $55,475,000 | – | 500,000 | +100.0% | 2.01% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $49,140,000 | – | 1,500,000 | +100.0% | 1.78% | – |
| New | ZIMVIE INC | $45,680,000 | – | 2,000,000 | +100.0% | 1.65% | – | |
| GSK | Sell | GLAXOSMITHKLINE PLCsponsored adr | $43,560,000 | -60.5% | 1,000,000 | -60.0% | 1.58% | -58.4% |
| OSUR | ORASURE TECHNOLOGIES INC | $28,815,000 | -22.0% | 4,250,000 | 0.0% | 1.04% | -17.9% | |
| NUVA | Buy | NUVASIVE INC | $28,350,000 | +440.2% | 500,000 | +400.0% | 1.02% | +469.4% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $28,125,000 | – | 300,000 | +100.0% | 1.02% | – |
| TEVA | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $25,823,000 | +17.2% | 2,750,000 | 0.0% | 0.93% | +23.4% | |
| INGN | Buy | INOGEN INC | $24,315,000 | +257.6% | 750,000 | +275.0% | 0.88% | +276.1% |
| SEM | New | SELECT MED HLDGS CORP | $23,990,000 | – | 1,000,000 | +100.0% | 0.87% | – |
| NKTR | Buy | NEKTAR THERAPEUTICS | $21,560,000 | -57.4% | 4,000,000 | +6.7% | 0.78% | -55.2% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $21,378,000 | +9.0% | 1,050,000 | 0.0% | 0.77% | +14.7% | |
| ZYME | Buy | ZYMEWORKS INC | $13,100,000 | -0.1% | 2,000,000 | +150.0% | 0.47% | +5.1% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $11,520,000 | +84.9% | 4,000,000 | +95.1% | 0.42% | +94.9% |
| GKOS | Buy | GLAUKOS CORP | $10,814,000 | +224.5% | 187,022 | +149.4% | 0.39% | +240.0% |
| EXEL | New | EXELIXIS INC | $6,801,000 | – | 300,000 | +100.0% | 0.25% | – |
| EVH | New | EVOLENT HEALTH INCcl a | $5,988,000 | – | 185,400 | +100.0% | 0.22% | – |
| SDC | Buy | SMILEDIRECTCLUB INC | $2,590,000 | +159.3% | 1,000,000 | +135.3% | 0.09% | +176.5% |
| RDUS | New | RADIUS HEALTH INC | $2,321,000 | – | 262,900 | +100.0% | 0.08% | – |
| INNV | Exit | INNOVAGE HLDG CORP | $0 | – | -350,000 | -100.0% | -0.06% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -500,000 | -100.0% | -0.19% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -1,633,333 | -100.0% | -0.22% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -1,300,000 | -100.0% | -1.04% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -3,000,000 | -100.0% | -1.20% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -250,000 | -100.0% | -2.06% | – |
| SNY | Exit | SANOFIcall | $0 | – | -1,500,000 | -100.0% | -2.58% | – |
| NVS | Exit | NOVARTIS AGcall | $0 | – | -1,000,000 | -100.0% | -3.01% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -450,000 | -100.0% | -3.40% | – |
| MRK | Exit | MERCK & CO INCcall | $0 | – | -2,000,000 | -100.0% | -5.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.